Development of cockroach immunotherapy by the Inner-City Asthma Consortium

Robert A. Wood, Alkis Togias, Jeremy Wildfire, Cynthia M. Visness, Elizabeth C. Matsui, Rebecca Gruchalla, Gurjit Hershey, Andrew H. Liu, George T. O'Connor, Jacqueline A. Pongracic, Edward Zoratti, Frederic Little, Mark Granada, Suzanne Kennedy, Stephen R. Durham, Mohamed H. Shamji, William W. Busse

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background Cockroach allergy is a key contributor to asthma morbidity in children living in urban environments. Objective We sought to document immune responses to cockroach allergen and provide direction for the development of immunotherapy for cockroach allergy. Methods Four pilot studies were conducted: (1) an open-label study to assess the safety of cockroach sublingual immunotherapy (SLIT) in adults and children; (2) a randomized, double-blind biomarker study of cockroach SLIT versus placebo in adults; (3) a randomized, double-blind biomarker study of 2 doses of cockroach SLIT versus placebo in children; and (4) an open-label safety and biomarker study of cockroach subcutaneous immunotherapy (SCIT) in adults. Results The adult SLIT trial (n = 54; age, 18-54 years) found a significantly greater increase in cockroach-specific IgE levels between the active and placebo groups (geometric mean ratio, 1.92; P <.0001) and a trend toward increased cockroach-specific IgG4 levels in actively treated subjects (P =.09) but no evidence of functional blocking antibody response. The pediatric SLIT trial (n = 99; age, 5-17 years) found significant differences in IgE, IgG, and IgG4 responses between both active groups and the placebo group but no consistent differences between the high- and low-dose groups. In the SCIT study the treatment resulted in significant changes from baseline in cockroach IgE, IgG4, and blocking antibody levels. The safety profile of cockroach immunotherapy was reassuring in all studies. Conclusions The administration of cockroach allergen by means of SCIT is immunologically more active than SLIT, especially with regard to IgG4 levels and blocking antibody responses. No safety concerns were raised in any age group. These pilot studies suggest that immunotherapy with cockroach allergen is more likely to be effective with SCIT.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology
Volume133
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Cockroaches
Immunotherapy
Asthma
Sublingual Immunotherapy
Immunoglobulin G
Blocking Antibodies
Placebos
Allergens
Immunoglobulin E
Safety
Biomarkers
Double-Blind Method
Antibody Formation
Hypersensitivity
Active Immunotherapy

Keywords

  • Cockroach
  • immunotherapy
  • inner city asthma
  • subcutaneous immunotherapy
  • sublingual immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Development of cockroach immunotherapy by the Inner-City Asthma Consortium. / Wood, Robert A.; Togias, Alkis; Wildfire, Jeremy; Visness, Cynthia M.; Matsui, Elizabeth C.; Gruchalla, Rebecca; Hershey, Gurjit; Liu, Andrew H.; O'Connor, George T.; Pongracic, Jacqueline A.; Zoratti, Edward; Little, Frederic; Granada, Mark; Kennedy, Suzanne; Durham, Stephen R.; Shamji, Mohamed H.; Busse, William W.

In: Journal of Allergy and Clinical Immunology, Vol. 133, No. 3, 03.2014.

Research output: Contribution to journalArticle

Wood, RA, Togias, A, Wildfire, J, Visness, CM, Matsui, EC, Gruchalla, R, Hershey, G, Liu, AH, O'Connor, GT, Pongracic, JA, Zoratti, E, Little, F, Granada, M, Kennedy, S, Durham, SR, Shamji, MH & Busse, WW 2014, 'Development of cockroach immunotherapy by the Inner-City Asthma Consortium', Journal of Allergy and Clinical Immunology, vol. 133, no. 3. https://doi.org/10.1016/j.jaci.2013.08.047
Wood, Robert A. ; Togias, Alkis ; Wildfire, Jeremy ; Visness, Cynthia M. ; Matsui, Elizabeth C. ; Gruchalla, Rebecca ; Hershey, Gurjit ; Liu, Andrew H. ; O'Connor, George T. ; Pongracic, Jacqueline A. ; Zoratti, Edward ; Little, Frederic ; Granada, Mark ; Kennedy, Suzanne ; Durham, Stephen R. ; Shamji, Mohamed H. ; Busse, William W. / Development of cockroach immunotherapy by the Inner-City Asthma Consortium. In: Journal of Allergy and Clinical Immunology. 2014 ; Vol. 133, No. 3.
@article{64094046ed0440f4b38969ea22a75b16,
title = "Development of cockroach immunotherapy by the Inner-City Asthma Consortium",
abstract = "Background Cockroach allergy is a key contributor to asthma morbidity in children living in urban environments. Objective We sought to document immune responses to cockroach allergen and provide direction for the development of immunotherapy for cockroach allergy. Methods Four pilot studies were conducted: (1) an open-label study to assess the safety of cockroach sublingual immunotherapy (SLIT) in adults and children; (2) a randomized, double-blind biomarker study of cockroach SLIT versus placebo in adults; (3) a randomized, double-blind biomarker study of 2 doses of cockroach SLIT versus placebo in children; and (4) an open-label safety and biomarker study of cockroach subcutaneous immunotherapy (SCIT) in adults. Results The adult SLIT trial (n = 54; age, 18-54 years) found a significantly greater increase in cockroach-specific IgE levels between the active and placebo groups (geometric mean ratio, 1.92; P <.0001) and a trend toward increased cockroach-specific IgG4 levels in actively treated subjects (P =.09) but no evidence of functional blocking antibody response. The pediatric SLIT trial (n = 99; age, 5-17 years) found significant differences in IgE, IgG, and IgG4 responses between both active groups and the placebo group but no consistent differences between the high- and low-dose groups. In the SCIT study the treatment resulted in significant changes from baseline in cockroach IgE, IgG4, and blocking antibody levels. The safety profile of cockroach immunotherapy was reassuring in all studies. Conclusions The administration of cockroach allergen by means of SCIT is immunologically more active than SLIT, especially with regard to IgG4 levels and blocking antibody responses. No safety concerns were raised in any age group. These pilot studies suggest that immunotherapy with cockroach allergen is more likely to be effective with SCIT.",
keywords = "Cockroach, immunotherapy, inner city asthma, subcutaneous immunotherapy, sublingual immunotherapy",
author = "Wood, {Robert A.} and Alkis Togias and Jeremy Wildfire and Visness, {Cynthia M.} and Matsui, {Elizabeth C.} and Rebecca Gruchalla and Gurjit Hershey and Liu, {Andrew H.} and O'Connor, {George T.} and Pongracic, {Jacqueline A.} and Edward Zoratti and Frederic Little and Mark Granada and Suzanne Kennedy and Durham, {Stephen R.} and Shamji, {Mohamed H.} and Busse, {William W.}",
year = "2014",
month = "3",
doi = "10.1016/j.jaci.2013.08.047",
language = "English (US)",
volume = "133",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Development of cockroach immunotherapy by the Inner-City Asthma Consortium

AU - Wood, Robert A.

AU - Togias, Alkis

AU - Wildfire, Jeremy

AU - Visness, Cynthia M.

AU - Matsui, Elizabeth C.

AU - Gruchalla, Rebecca

AU - Hershey, Gurjit

AU - Liu, Andrew H.

AU - O'Connor, George T.

AU - Pongracic, Jacqueline A.

AU - Zoratti, Edward

AU - Little, Frederic

AU - Granada, Mark

AU - Kennedy, Suzanne

AU - Durham, Stephen R.

AU - Shamji, Mohamed H.

AU - Busse, William W.

PY - 2014/3

Y1 - 2014/3

N2 - Background Cockroach allergy is a key contributor to asthma morbidity in children living in urban environments. Objective We sought to document immune responses to cockroach allergen and provide direction for the development of immunotherapy for cockroach allergy. Methods Four pilot studies were conducted: (1) an open-label study to assess the safety of cockroach sublingual immunotherapy (SLIT) in adults and children; (2) a randomized, double-blind biomarker study of cockroach SLIT versus placebo in adults; (3) a randomized, double-blind biomarker study of 2 doses of cockroach SLIT versus placebo in children; and (4) an open-label safety and biomarker study of cockroach subcutaneous immunotherapy (SCIT) in adults. Results The adult SLIT trial (n = 54; age, 18-54 years) found a significantly greater increase in cockroach-specific IgE levels between the active and placebo groups (geometric mean ratio, 1.92; P <.0001) and a trend toward increased cockroach-specific IgG4 levels in actively treated subjects (P =.09) but no evidence of functional blocking antibody response. The pediatric SLIT trial (n = 99; age, 5-17 years) found significant differences in IgE, IgG, and IgG4 responses between both active groups and the placebo group but no consistent differences between the high- and low-dose groups. In the SCIT study the treatment resulted in significant changes from baseline in cockroach IgE, IgG4, and blocking antibody levels. The safety profile of cockroach immunotherapy was reassuring in all studies. Conclusions The administration of cockroach allergen by means of SCIT is immunologically more active than SLIT, especially with regard to IgG4 levels and blocking antibody responses. No safety concerns were raised in any age group. These pilot studies suggest that immunotherapy with cockroach allergen is more likely to be effective with SCIT.

AB - Background Cockroach allergy is a key contributor to asthma morbidity in children living in urban environments. Objective We sought to document immune responses to cockroach allergen and provide direction for the development of immunotherapy for cockroach allergy. Methods Four pilot studies were conducted: (1) an open-label study to assess the safety of cockroach sublingual immunotherapy (SLIT) in adults and children; (2) a randomized, double-blind biomarker study of cockroach SLIT versus placebo in adults; (3) a randomized, double-blind biomarker study of 2 doses of cockroach SLIT versus placebo in children; and (4) an open-label safety and biomarker study of cockroach subcutaneous immunotherapy (SCIT) in adults. Results The adult SLIT trial (n = 54; age, 18-54 years) found a significantly greater increase in cockroach-specific IgE levels between the active and placebo groups (geometric mean ratio, 1.92; P <.0001) and a trend toward increased cockroach-specific IgG4 levels in actively treated subjects (P =.09) but no evidence of functional blocking antibody response. The pediatric SLIT trial (n = 99; age, 5-17 years) found significant differences in IgE, IgG, and IgG4 responses between both active groups and the placebo group but no consistent differences between the high- and low-dose groups. In the SCIT study the treatment resulted in significant changes from baseline in cockroach IgE, IgG4, and blocking antibody levels. The safety profile of cockroach immunotherapy was reassuring in all studies. Conclusions The administration of cockroach allergen by means of SCIT is immunologically more active than SLIT, especially with regard to IgG4 levels and blocking antibody responses. No safety concerns were raised in any age group. These pilot studies suggest that immunotherapy with cockroach allergen is more likely to be effective with SCIT.

KW - Cockroach

KW - immunotherapy

KW - inner city asthma

KW - subcutaneous immunotherapy

KW - sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84896720589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896720589&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2013.08.047

DO - 10.1016/j.jaci.2013.08.047

M3 - Article

VL - 133

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -